July 30th 2025
Exonate initiates a phase 2b trial for EXN407, a groundbreaking eye drop treatment for diabetic retinopathy
July 29th 2025
Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography
July 28th 2025
According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”
July 25th 2025
Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes
July 24th 2025
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease
The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests
New microbial strain produces high yields of lutein for AMD, cataract prevention
Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis
Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
Cannabis has been shown to reduce microglial activity, expression of inflammatory cytokines and retinal neurotoxicity
FDA agrees to expand Atsena's gene therapy trial for XLRS treatment
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001
Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia
Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration
The imaging innovation project is named after the company's co-founder Gerhard Zinser, PhD
Long-duration spaceflight tests the limits of telemedicine
In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained
Patients with high genetic risk of AMD should avoid instant coffee, investigators say
Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption
European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval
With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.
The significance of FLIO in diabetic eye disease
Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers
How remote retinal imaging raises the bar across service, research and education
Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium
Differentiating physiology from pathology in the paediatric vitreous
Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture
Imaging the ellipsoid zone line could change the global approach to clinical trials
Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium
Neeraj Dhaun, MD, PhD, says advances in OCT tech may positively impact patients with chronic kidney disease
Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium
Gereon Hüttmann, PhD, introduces holographic OCT to a new audience
The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium
Ruth Hogg, PhD, says NICOLA data emphasise the value of multicolor images
Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium
Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)
Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.
An implantable option bridges the gap for patients with AMD
Long-term benefits and vision preservation using an extended macular vision IOL
EU issues CE mark for AI therapy planning assistant from deepeye Medical
The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe
Metabolomic profiling could identify stage-specific diabetic retinopathy biomarkers
Lysine, proline and arginine levels progressively increased from non-proliferative DR to proliferative DR stages
Research indicates B vitamins and choline provide neuroprotection against glaucoma
Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death
EMA issues CE mark for DREAM OCT (Intalight)
The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO
Retinal microvascular changes in patients with systemic lupus erythematosus: Importance of OCTA
The biomarkers are especially crucial for patients with lupus nephritis
Moorfields, Topcon, IoO announce partnership launch of Cascader
Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.
LuxIA receives CE-MDR certification
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.
Daniela Ferrara appointed by Topcon Healthcare as CMO
Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy
Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch
The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)
Regeneron announces US FDA complete response letter for aflibercept 8 mg (Eylea HD) supplemental Biologics License Application
The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg